

# SARS-CoV-2 on Ocular Surfaces in a Cohort of Patients With COVID-19 From the Lombardy Region, Italy

Claudio Azzolini, MD; Simone Donati, MD; Elias Premi, MD; Andreina Baj, MD; Claudia Siracusa, BMedBiol; Angelo Genoni, BMedSci; Paolo A. Grossi, MD; Lorenzo Azzi, MD; Fausto Sessa, MD; Francesco Dentali, MD; Paolo Severgnini, MD; Giulio Minoja, MD; Luca Cabrini, MD; Maurizio Chiaravalli, MD; Giovanni Veronesi, MD; Giulio Carcano, MD; Lorenzo S. Maffioli, MD; Angelo Tagliabue, MD

[+ Supplemental content](#)

**IMPORTANCE** Since February 2020, coronavirus disease 2019 (COVID-19) has spread rapidly all over the world, with an epidemiological cluster in Lombardy, Italy. The viral communicability may be mediated by various body fluids, but insufficient information is available on the presence of the virus in human tears.

**OBJECTIVES** To investigate the rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in tears collected from patients with COVID-19 by means of real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) assay and to assess the association of virus presence with concomitant clinical conditions.

**DESIGN, SETTING, AND PARTICIPANTS** Cross-sectional study conducted between April 9 and May 5, 2020. The setting was intensive care units at Azienda Socio-Sanitaria Territoriale (ASST) Sette-Laghi Hospital, University of Insubria, in Varese, Lombardy, Italy. A conjunctival swab was performed in 91 patients hospitalized for COVID-19, which was clinically diagnosed by rRT-PCR assay on nasopharyngeal swabs and by radiological imaging. Conjunctival swabs from 17 additional healthy volunteer participants with no symptoms of COVID-19 were examined to evaluate the availability and applicability of the conjunctival swab test.

**EXPOSURE** SARS-CoV-2 detection by means of rRT-PCR assay performed on the collected samples obtained by conjunctival swabs.

**MAIN OUTCOMES AND MEASURES** Conjunctival swab and nasopharyngeal swab results are reported, as well as demographic and clinical data.

**RESULTS** A total of 108 participants (mean [SD] age, 58.7 [14.2] years; 55 female and 53 male) were tested for SARS-CoV-2 using rRT-PCR assay, including 91 patients hospitalized with COVID-19 and 17 were healthy volunteers. SARS-CoV-2 was found on the ocular surface in 52 of 91 patients with COVID-19 (57.1%; 95% CI, 46.3%-67.5%), with a wide variability in the mean viral load from both eyes. Among a subset of 41 patients, concordance of 63.0% (95% CI, 41.0%-81.0%) was found between positive conjunctival and nasopharyngeal swab test results when performed within 2 days of each other. In 17 of these patients, nasopharyngeal swab results were negative for SARS-CoV-2. In 10 of these 17 patients, conjunctival swab results were positive for the virus.

**CONCLUSIONS AND RELEVANCE** In this study, SARS-CoV-2 RNA was found on the ocular surface in a large part of this cohort of patients with COVID-19, although the infectivity of this material could not be determined. Because patients may have positive test results with a conjunctival swab and negative results with a nasopharyngeal swab, use of the slightly invasive conjunctival swab may be considered as a supplementary diagnostic test.

*JAMA Ophthalmol.* doi:10.1001/jamaophthalmol.2020.5464  
Published online March 4, 2021.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Claudio Azzolini, MD, Unit of Ophthalmology, Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Via Guicciardini 9, 21100 Varese, Italy ([claudio.azzolini@uninsubria.it](mailto:claudio.azzolini@uninsubria.it)).

In February 2020, coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome appeared in China<sup>1-12</sup> and rapidly spread all over the world, with an epidemiological cluster in Northern Italy.<sup>9,13-17</sup> Several reasons explain this rapid diffusion in the Lombardy region of Italy. The high population density with increased possibility of interpersonal contact, the prevalence of respiratory pathologies because of pollution, contact with the Chinese population for travel and business, and the nonwindy, temperate climate conditions promote the persistence of a virus in the environment. More than 90 000 citizens from the Lombardy region have officially been affected by the disease, with a high death toll reported.<sup>18</sup> The actual numbers are certainly much higher.

The etiological factor responsible for the disease has been identified in a new betacoronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus has high human transmission via airways but has a medium virulence.<sup>19</sup> Therefore, many people test positive for the presence of the virus without any signs of disease. SARS-CoV-2 RNA has been found in the nasopharyngeal tract and bronchial drainage,<sup>1</sup> in saliva,<sup>20</sup> in tears,<sup>21-24</sup> in urine,<sup>25</sup> and in feces<sup>26</sup> but not in seminal fluids.<sup>27</sup>

The objective of the present study was to use real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) analysis to investigate the presence of SARS-CoV-2 in tears collected from patients with COVID-19. We also aimed to assess the association of virus presence with concomitant systemic and local clinical conditions.

## Methods

### Study Design

This cross-sectional study was conducted between April 9 and May 5, 2020, in intensive care units at Azienda Socio-Sanitaria Territoriale (ASST) Sette-Laghi Hospital, University of Insubria, in Varese, Lombardy, Italy. A conjunctival swab was performed in 2 cohorts (patients hospitalized for COVID-19 and healthy participants) and was examined by rRT-PCR assay to detect the presence of SARS-CoV-2. The study was carried out in accordance with the guidelines of the Declaration of Helsinki<sup>28</sup> and subsequent revisions and with the authorization of the Ethics Committee and Institutional Advisory Board of ATS (Agenzia per la Tutela della Salute) Insubria in Varese, Italy. Oral informed consent was obtained from study participants, who did not receive a stipend. All collected data were deidentified and protected by privacy safeguards. The study is registered on ClinicalTrials.gov (Identifier: [NCT04402853](https://clinicaltrials.gov/ct2/show/study/NCT04402853)).

We collected specimens and clinical data from 176 eyes of 91 patients hospitalized for COVID-19 in 3 different intensive care units (ICUs). Clinical diagnosis of COVID-19 disease was confirmed by nasopharyngeal swab positivity, symptoms of severe respiratory distress, characteristic chest imaging (radiograph and computed tomographic scan with ground glass opacifications), and lymphopenia.<sup>5,8</sup> All patients were from the central-northern area of Lombardy. We excluded patients with continuous positive airway pressure helmets or similar respi-

### Key Points

**Question** What is the qualitative and quantitative presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on the ocular surface in patients with coronavirus disease 2019 (COVID-19) hospitalized in intensive care units at a university hospital in Lombardy, Italy?

**Findings** Using reverse transcription-polymerase chain reaction assay, this study found that SARS-CoV-2 was present on the ocular surface in 52 of 91 patients with COVID-19 (57.1%). The virus may also be detected on ocular surfaces in patients with COVID-19 when the nasopharyngeal swab is negative.

**Meaning** These results suggest that SARS-CoV-2 may diffuse from ocular surfaces to the body.

ratory devices, as recommended by anesthesiologists for the safety of patients. We also collected specimens from 34 eyes of 17 healthy volunteer participants (10 women and 7 men) to evaluate the availability and applicability of the conjunctival swab test.


Before the conjunctival swab procedure, an ophthalmologist (E.P.) examined the status of eyelids, conjunctiva, and cornea. Eye examinations were done at the bedside without a slit-lamp. Clinical information about hospitalization timing, results of diagnostic and serological examinations, and type of respiratory device was recorded using a smartphone during the procedure and later transcribed. We also documented results of the last nasopharyngeal swab for each patient.

The sampling procedure (**Figure 1**) was performed at the bedside by the same ophthalmologist (E.P.) in both eyes. The samples were obtained without topical anesthesia and after sufficient time had elapsed since lacrimal substitutes had been used. The conjunctival swabs were performed in the right eye first, and paired (right and left) conjunctival swabs were kept separate. A sample was available from only 1 eye in 6 patients (right eye in 4 patients and left eye in 2 patients) because of difficulties during the sampling procedure (lack of cooperation or technical problems). The conjunctival samples were absorbed by a dedicated swab with short fiber strands optimized for virus samples, with minimum patient discomfort (FLOQSwabs; COPAN, Brescia, Italy). Swabs for sampling of tears are shown in the eFigure in [Supplement 1](#).

The conjunctival swab was then inserted into a dedicated vial with a transport fluid (UTM-RT-Hanks balanced salt solution enriched with proteins and sugars and with a neutral pH; COPAN). The use of this fluid ensures that the samples are preserved in ambient conditions for up to 48 hours. The vials were delivered to the laboratory within 45 minutes and stored at  $-80^{\circ}\text{C}$  after virus inactivation for 1 minute at  $90^{\circ}\text{C}$ . The laboratory researcher (A.B.) then processed the samples within 2 days.

From the vial, 140  $\mu\text{L}$  of each sample was subjected to RNA extraction (QIAmp viral RNA mini kit; QIAGEN) and eluted in 60  $\mu\text{L}$ . One-step real-time polymerase chain reaction (PCR) was performed (Luna universal qPCR master mix; New England Biolabs) from 5  $\mu\text{L}$  of extracted RNA. Forward (5'-ACCTTCCCAGG-TAACAAACCA-3') and reverse (5'-TTACCTTTTCGGTCACACCCG-3') primers targeting the 5' untranslated region (5'UTR) of

Figure 1. Procedure for Sampling of Tears



SARS-CoV-2 were used. Primers were designed using software (CLC Genomics Workbench; QIAGEN), and their specificity was checked using the BLAST database.<sup>29</sup>

Samples were run in 4 replicates together with a quantified positive control (SARS-CoV-2 RNA control; Twist Bioscience) on a PCR system (QuantStudio 5 real-time PCR; Thermo Fisher Scientific), with an annealing temperature of 60 °C. Provided at a concentration of 10<sup>6</sup> copies/μL, serial dilutions of RNA control from 10<sup>4</sup> to 10 copies/μL were used to construct a standard curve to perform an absolute quantification. Results were expressed as copies/μL (a positive viral load was defined as >50 copies/μL in at least 1 eye) according to the detection and amplification ability of the rRT-PCR instrument. In case of an uncertain result, an end point rRT-PCR and subsequent sequencing of the 5'UTR region were performed on the same RNA.

Retrotranscription, amplification, and sequence reaction were performed with a thermal cycler (Veriti; Perkin Elmer), and 251-base pair amplicon detection was performed with a chip (LabChipGx Touch24; Perkin Elmer). Obtained amplicons were sequenced by the Sanger method (SeqStudio genetic analyzer; Thermo Fisher Scientific). All collected specimens have been preserved in vials at -80 °C for future research.

Electronic medical records (eTable in Supplement 2) were uploaded and stored in a dedicated database. The system was provided by a medical platform in a data warehouse in Milan, Italy (Eumeda platform hosted by Aruba Business srl) to ensure data security and uninterrupted availability. The platform enabled efficient and immediate data visibility and rapid data extraction.

### Statistical Analysis

Because of a lack of data regarding the prevalence of positive conjunctival swab results in the Italian COVID-19 population, there was no formal sample size calculation. Given the size of the reference population for the hospital and the epidemic trend curve at the start of the study, we expected to accrue approximately 100 patients. This size would enable estimation of the proportion of positive tests with a precision of about 10%.<sup>30</sup>

We summarized demographic and clinical features of eligible participants. Mean and standard proportions or absolute and relative frequencies were used for continuous and dis-

crete variables, respectively. The same statistics were reported in patients with positive vs negative conjunctival swab results and were compared using *t* tests or  $\chi^2$  tests for continuous and discrete or dichotomous variables, respectively. Time between conjunctival swab performance and COVID-19 diagnosis was reported in weeks (range, 1-4 weeks).

We estimated the rate of patients with positive conjunctival swab results in the overall sample since COVID-19 diagnosis using the exact binomial distribution for 95% CIs. The same analyses were replicated for the latest available nasopharyngeal swab. In addition, we reported the prevalence of concordant-positive conjunctival swab results in both eyes. The viral load distribution variable was defined as the average between eyes in patients with concordant-positive results and as the viral load in the positive eye for individuals with positive conjunctival swab results in 1 eye only. We estimated the rate of both positive conjunctival and nasopharyngeal swabs, as well as both negative conjunctival and nasopharyngeal swabs, and the 95% CIs from the exact binomial distribution. The analyses were performed using SAS, 9.4 release (SAS Institute Inc), and graphics were drawn with R (The R Project for Statistical Computing). All *P* values were 2-sided but *P* values were not adjusted for multiple analyses.

## Results

A total of 108 participants (mean [SD] age, 58.7 [14.2] years; 55 female and 53 male) were tested for SARS-CoV-2 using rRT-PCR assay. Ninety-one were hospitalized patients with COVID-19, and 17 were healthy participants. The mean (SD) age of the healthy participants was 49.5 (5.2) years. All conjunctival swabs were negative for SARS-CoV-2 among the healthy participants. The evaluation of the availability and applicability of the conjunctival swab test in these 17 showed that the procedure is annoying for the participant and easily repeatable by the operator.

Characteristics of the 91 hospitalized patients are shown in Table 1. Of these, 58 patients (63.7%) had positive nasopharyngeal swab results and 33 (36.3%) had negative nasopharyngeal swab results.

SARS-CoV-2 was found on the ocular surface in 52 of the 91 patients hospitalized with COVID-19 (57.1%; 95% CI, 46.3%-

**Table 1. Demographic and Clinical Characteristics of 91 Patients Overall and by Conjunctival Swab Positivity or Negativity for SARS-CoV-2**

| Variable  | No. (%)               |  |                                     |
|---|-----------------------|--|-------------------------------------|
|   | All patients (N = 91) | Conjunctival swab positive (n = 52) <sup>a</sup> | Conjunctival swab negative (n = 39) |
| Age, mean (SD), y   | 67.9 (13.2)           | 68.3 (13.5)                                      | 67.3 (12.9)                         |
| Sex   |                       |  |                                     |
| Female  | 45 (50.5)             | 27 (51.9)  | 18 (46.2)                           |
| Male  | 46 (49.5)             | 25 (48.1)  | 21 (53.8)                           |
| Nasopharyngeal swab test                                      |                       |  |                                     |
| Positive  | 58 (63.7)             | NA   | NA                                  |
| Negative  | 33 (36.3)             | NA   | NA                                  |
| Comorbidities at COVID-19 diagnosis                           |                       |  |                                     |
| Cardiovascular diseases                                       | 53 (58.2)             | 31 (59.6)  | 22 (56.4)                           |
| Respiratory diseases  | 13 (14.3)             | 9 (17.3)   | 4 (10.3)                            |
| Autoimmune diseases   | 22 (24.2)             | 15 (28.8)  | 7 (17.9)                            |
| Neurological diseases   | 32 (35.2)             | 17 (32.7)  | 15 (38.5)                           |
| Endocrine diseases  | 65 (71.4)             | 38 (73.1)  | 27 (69.2)                           |
| Ocular diseases   | 5 (5.5)               | 2 (3.8)  | 3 (7.7)                             |
| Previous ocular surgery                                       | 3 (3.3)               | 2 (3.8)  | 1 (2.6)                             |
| Ocular signs <sup>b</sup>                                     |                       |  |                                     |
| Hyperemia   | 3 (3.3)               | 3 (5.8)  | 0                                   |
| Secretions  | 3 (3.3)               | 3 (5.8)  | 0                                   |
| Blepharitis   | 5 (5.5)               | 4 (7.7)  | 1 (2.6)                             |
| Other signs   | 8 (8.8)               | 7 (13.5)   | 1 (2.6)                             |
| Hospitalization department                                    |                       |  |                                     |
| Infectious diseases department                                | 31 (34.1)             | 19 (36.5)  | 12 (30.8)                           |
| High intensity medicine department                            | 42 (46.2)             | 24 (46.2)  | 18 (46.2)                           |
| Intensive care department                                     | 18 (19.8)             | 9 (17.3)   | 9 (23.1)                            |
| Respiratory devices at time of conjunctival swab <sup>c</sup> |                       |  |                                     |
| Ambient air   | 21 (23.1)             | 9 (17.3)   | 12 (30.8)                           |
| Cannulas  | 16 (17.6)             | 10 (19.2)  | 6 (15.4)                            |
| Venturi mask  | 30 (33.0)             | 19 (36.5)  | 11 (28.2)                           |
| Reservoir mask  | 13 (14.3)             | 8 (15.4)   | 5 (12.8)                            |
| Intubation  | 11 (12.1)             | 6 (11.5)   | 5 (12.8)                            |

Abbreviations: COVID-19, coronavirus disease 2019; NA, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup> A positive viral load was defined as greater than 50 copies/ $\mu$ L in at least 1 eye.

<sup>b</sup> Presence of signs or symptoms in at least 1 eye.

<sup>c</sup> Listed from least to greatest intensity (excluding patients with continuous positive airway pressure helmets or similar respiratory devices, as recommended by anesthesiologists for the safety of patients).

67.5%). There was a wide variability in the average viral load from both eyes (median [range], 284 copies/ $\mu$ L [29-45 000 copies/ $\mu$ L]).

The virus was present in both eyes in 31 of 52 patients. Several patients (22 of 31 [71%]) had a slight difference in viral load values between the 2 eyes. A discrepancy in conjunctival swab results within the same patient (ie, 1 eye positive and 1 eye negative) was observed in 21 of 91 patients (23.1%); a viral load greater than 50 copies/ $\mu$ L was detected in 1 eye. The highest viral load of a single eye (up to 90 000 copies/ $\mu$ L) was found in patients with the virus detected in both eyes. The lowest value of viral load found in patients considered positive for the conjunctival swab (58 copies/ $\mu$ L) was found in patients in whom the virus was detected in 1 eye only.

No association was found between virus detection and comorbidities at COVID-19 diagnosis. A slightly higher prevalence of ocular signs or symptoms of surface inflammation in at least 1 eye was present among patients with positive conjunctival swab results than among those with negative con-

conjunctival swab results. Neither the hospital department type nor the respiratory device at the time of conjunctival swab was associated with the presence of the virus on the ocular surface (Table 1).

Fifty-eight (63.7%; 95% CI, 53.0%-73.6%) of the hospitalized patients had positive nasopharyngeal swab results (Table 2). No differences in the number of positive conjunctival swabs were found among the 91 hospitalized patients according to time since COVID-19 diagnosis and clinical signs.

Forty-one patients had both nasopharyngeal and conjunctival swabs performed on the same day or within 2 days. A positive concordance of 63.0% (95% CI, 41.0%-81.0%) was found between conjunctival and nasopharyngeal swabs when performed within 2 days of each other. Among these 41 patients, only 7 of 17 patients (41.2%; 95% CI, 18.0%-67.0%) tested had negative conjunctival and nasopharyngeal swab results (Table 3). Again, 10 of these 17 patients had negative nasopharyngeal swab results but positive conjunctival swab results, with a mean viral load value of 881.7 copies/ $\mu$ L (range, 29-6900 copies/ $\mu$ L).

**Table 2. Comparison of Patients With Positive Conjunctival Swab Results and Those With Positive Nasopharyngeal Swab Results<sup>a</sup>**

| Variable                          | Conjunctival swab positive               |                         | Nasopharyngeal swab positive             |                         |
|-----------------------------------|--|-------------------------|--|-------------------------|
|                                   | No. <sup>b</sup> /total No. <sup>c</sup> | % (95% CI) <sup>d</sup> | No. <sup>e</sup> /total No. <sup>c</sup> | % (95% CI) <sup>d</sup> |
| All patients                      | 52/91                                    | 57.1 (46.3-67.5)        | 58/91                                    | 63.7 (53.0-73.6)        |
| Time since COVID-19 diagnosis, wk |  |                         |  |                         |
| 1                                 | 14/26                                    | 53.9 (33.3-73.4)        | NA                                       | 73.3 (58.1-85.4)        |
| 2                                 | 15/27                                    | 55.6 (35.3-74.5)        | NA                                       | 82.4 (56.6-96.2)        |
| 3                                 | 10/14                                    | 71.4 (41.9-91.6)        | NA                                       | 33.3 (0.1-70.1)         |
| ≥4                                | 13/24                                    | 54.2 (32.8-74.5)        | NA                                       | 40.0 (19.1-64.0)        |
| χ <sup>2</sup> Test P value       | NA                                       | .71                     | NA                                       | .005                    |

Abbreviations: COVID-19, coronavirus disease 2019; NA, not applicable.

<sup>a</sup> A positive viral load was defined as greater than 50 copies/μL in at least 1 eye.

<sup>b</sup> Number of patients with positive conjunctival swab results.

<sup>c</sup> Number of patients with a COVID-19 diagnosis.

<sup>d</sup> The 95% CIs are from the exact binomial distribution.

<sup>e</sup> Number of patients with positive nasopharyngeal swab results.

**Table 3. Results of Conjunctival and Nasopharyngeal Swab Tests Among 41 Patients With Both Tests Performed Within 2 Days**

| Variable                          | Nasopharyngeal swab positive             |                                  | Nasopharyngeal swab negative             |                                  |
|-----------------------------------|--|----------------------------------|--|----------------------------------|
|                                   | No. <sup>a</sup> /total No. <sup>b</sup> | Prevalence (95% CI) <sup>c</sup> | No. <sup>d</sup> /total No. <sup>e</sup> | Prevalence (95% CI) <sup>c</sup> |
| All patients                      | 15/24                                    | 0.63 (0.41-0.81)                 | 7/17                                     | 0.41 (0.18-0.67)                 |
| Time since COVID-19 diagnosis, wk |  |                                  |  |                                  |
| 1                                 | 7/8                                      | 0.88 (0.47-0.99)                 | 2/6                                      | 0.33 (0.04-0.78)                 |
| ≥2                                | 8/16                                     | 0.50 (0.25-0.75)                 | 5/11                                     | 0.45 (0.17-0.77)                 |

Abbreviation: COVID-19, coronavirus disease 2019.

<sup>a</sup> Number of patients with positive conjunctival swab results.

<sup>b</sup> Number of patients in whom the results of the last nasopharyngeal swab were positive.

<sup>c</sup> The 95% CIs are from the exact binomial distribution.

<sup>d</sup> Number of patients with negative conjunctival swab results.

<sup>e</sup> Number of patients in whom the results of the last nasopharyngeal swab were negative.

Figure 2 shows the median values and 25th to 75th percentiles of viral load in 52 patients with positive conjunctival swab results. The median viral load was 1120 copies/μL for week 1, 303 copies/μL for week 2, 424 copies/μL for week 3, and 295 copies/μL for week 4. All 34 eyes of the 17 healthy control participants tested negative for SARS-CoV-2.

## Discussion

In this study, SARS-CoV-2 was present on the ocular surface in patients with COVID-19 and was quantitatively and qualitatively detectable, but the infectivity of this material and thus the definitive clinical relevance could not be determined from this study. The high rates reported in this study (Tables 1 and 2) may be attributable to different reasons. The sample collections were performed by the same ophthalmologist following a precisely defined procedure and using a dedicated swab for molecular testing. Tear samples were processed in the same laboratory, which has extensive experience in processing thousands of body fluid samples a day from patients with COVID-19. Time between sample incubation and processing was minimized, as described in the Methods section, and a real-time PCR primer targeted to the 5'UTR region of SARS-CoV-2 was used in all cases.<sup>20</sup>


The few positive coronavirus conjunctival swab results reported in the literature<sup>21-24,31-35</sup> may be because of several critical issues in sampling and laboratory processes. First, the specimen collection procedures were not well explained in the articles and may be not reproducible. Second,

samples were analyzed in various laboratories using different rRT-PCR procedures within the same study. Third, the tear samples may have been incubated with various fluids. Fourth, the interval from acquisition to processing was not stated, which may have altered the results if high. Fifth, knowledge about virus behavior and characteristics has increased in the last few months, with growing availability of detection methods.

There was a wide variability in the mean viral load from both eyes in the studied cohort. Several patients had a slight difference between the 2 eyes. A discrepancy in conjunctival swab results (ie, 1 eye positive and 1 eye negative) was observed in 21 of 91 patients (23.1%). The variability in viral load among the patients and the discrepancy between eyes might have different explanations. The presence of the virus on the eye surface could be variable (sometimes low or undetectable). In addition, the sampling procedure may be uncomfortable and poorly done, especially when performed in the second eye.

In comparison of conjunctival swab and nasopharyngeal swab results in 41 patients with COVID-19 when tests were performed within 2 days of each other, we observed a positive concordance of 63.0% (95% CI, 41.0%-81.0%) between the results of the tests (Table 3, left column). In the same subgroup, we observed that among the 17 patients with COVID-19 that had a negative nasopharyngeal swab test result, 10 patients had a positive conjunctival swab (Table 3, right column). These patients demonstrated a high viral load (approximate mean, 1000 copies/μL) in tear samples, pointing out that the virus was present in the body despite

**Figure 2. Viral Load in 52 Conjunctival Swab–Positive Patients According to Time Since COVID-19 Diagnosis**



Shown are the median values and 25th to 75th percentiles of viral load. COVID-19 indicates coronavirus disease 2019.

being undetectable in the nasopharyngeal tract. Studies<sup>26,36</sup> have reported the presence of SARS-CoV-2 in various body fluids, but it was not always detectable in the nasopharyngeal tract in those cases.

There could be many different explanations for the presence of the virus on the ocular surface, but these reasons are all speculative. For example, direct contagion from airborne droplets by infected people is possible, as well as particles diffused in the atmosphere.<sup>1,9</sup> Atmospheric particulates are known to function as carriers for many chemical and biological contaminants, including viruses.<sup>37</sup> By piggybacking, viruses adhere to atmospheric fine powders<sup>38</sup> consisting of solid or liquid particles that are able to remain in the atmosphere for hours, days, or longer, especially in a nonwindy and polluted climate like the Po Valley in Lombardy.<sup>39</sup> Increasing numbers of patients with COVID-19 have been diagnosed in this region since March 3, 2020, corresponding to excessive atmospheric particulate levels<sup>40</sup> recorded from February 10 to 29, 2020. This interval is recognized as the incubation period before clinical manifestation of the virus.

Regarding other means of viral diffusion into the eye, the literature reports direct contact with infected surfaces by the hands and transport to the mouth, nose, or other mucous membranes, such as the conjunctiva.<sup>1,9,41,42</sup> SARS-CoV-2 remains viable in aerosol form for hours even with a decreased infectious titer.<sup>43</sup> It may stay on various surfaces longer. For example, it can be detected on plastic for up to 72 hours, although with a great reduction in virus titer (ie, the virus could be viable on dry surfaces until 72 hours even if a reduction of <10-fold in titer is measured).<sup>44</sup> We speculate that the virus may diffuse in the fluid of the tears from lacrimal glands because of systemic viremia, as has been demonstrated for HIV.<sup>45</sup> Among the theories described herein, direct contagion from airborne droplets seems to be the most likely theory.

When SARS-CoV-2 infects the eyes from the conjunctiva, where airborne droplets land, the virus may diffuse

into the body through the nasolacrimal duct, which is a pathway to the pharynx.<sup>46-48</sup> This contagion occurs despite the use of protective masks for the mouth and nose. The clinical case of the deceased ophthalmologist Dr Li Wenliang of Wuhan, China, described in the literature may be an example of such COVID-19 spread.<sup>49</sup> Although the infectivity of the viral material detected in the present study is unknown, these results support the use of eye protection for people working in environments where infection through the ocular route is feasible.<sup>50-58</sup> Eye protection probably should be considered if viral material might exceed certain limits, especially in the absence of wind or indoor systems designed to clear the air.

We evaluated the association between positive conjunctival swab results and the use of different respiratory devices<sup>9</sup> in patients with COVID-19, as considered in the eligibility criteria stated in the Methods section of our study. It is speculated that invasive maneuvers and respiratory devices like continuous positive airway pressure masks or helmets may increase the risk of viral diffusion by creating a closed environment around the head.<sup>59</sup> No associations were found between respiratory device use and conjunctival swab results. This finding indicates that respiratory devices may not be associated with viral diffusion of SARS-CoV-2 into tears (Table 1).

We observed a low rate of ocular signs or symptoms in patients positive for the conjunctival swab (Table 1). A persistent palpebral edema could be secondary to the prone position of a patient for respiratory reasons, as we find in patients a few days after ocular surgery when a prone position is necessary.<sup>60</sup> However, data in the current literature are discordant about eye surface inflammatory involvement because many patients show different signs and symptoms, with difficult grading and evaluation.<sup>61</sup>

In respiratory airways, the infection and cellular entry of SARS-CoV-2 are mediated by the spike glycoprotein of coronavirus and the host cellular SARS-CoV receptor for angiotensin-converting enzyme 2 (ACE2).<sup>62</sup> Type II transmembrane serine protease (TMPRSS2) is required to promote SARS-CoV-2 entry by ACE2 cleavage to promote viral uptake.<sup>63</sup> However, the expression of ACE2 receptors in anterior ocular tissues, such as the conjunctiva or cornea, has yet to be established. More research exploring the hypothesis of SARS-CoV-2 ocular infection through ACE2 may be warranted. Various clinical signs of SARS-CoV-2 have been described in the literature,<sup>64</sup> but they appear to be nonspecific and different from viral conjunctivitis and keratitislike adenovirus. Knowing that SARS-CoV-2 is present in the conjunctiva may represent future scenarios for immunological and body reaction therapy in these patients.

Regarding public health regulations, the current screening test for the detection of SARS-CoV-2 infection is rRT-PCR assay on respiratory specimens. This screening requires specific training for operators and is susceptible to false-negative results.<sup>65</sup> Detection tests using other body fluids are promising. Samples of tears and saliva are easily provided by the patients, they do not require specialized training for collection, and the procedure may not be uncomfortable.<sup>20-22</sup>

## Limitations

This study has some limitations. We could not determine the infectivity of the viral material detected and thus the definitive clinical relevance. Other limitations include the cross-sectional design of the study, which lacks long-term prospective evaluation of the patients. The limited number of negative conjunctival swab in the presence of a positive nasopharyngeal test in patients with COVID-19 may be due to difficulties in patients' tears sampling and current overall limited knowledge. To evaluate the availability and applicability of the conjunctival swab test, we studied a group of 17 healthy volunteers with no symptoms or signs of COVID-19. All conjunctival swabs were negative for SARS-CoV-2 among these participants.

## Conclusions

This cross-sectional study found that SARS-CoV-2 RNA was present on ocular surfaces in a large portion of the study cohort, although the infectivity of this material could not be determined from the study. Findings suggest that individuals with COVID-19 may test positive with a conjunctival swab and test negative with a nasopharyngeal swab. The slightly invasive conjunctival swab may be considered as a supplementary diagnostic test for COVID-19. Ongoing development of procedures and laboratory testing tools may improve the ability to investigate this use in the future.

## ARTICLE INFORMATION

**Accepted for Publication:** October 10, 2020.

**Published Online:** March 4, 2021.

doi:10.1001/jamaophthalmol.2020.5464

**Author Affiliations:** Unit of Ophthalmology, Azienda Socio-Sanitaria Territoriale (ASST) dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy (Azzolini, Donati, Premi); Laboratory of Microbiology, ASST dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy (Baj); Laboratory of Medicine, Service of Cytogenetics and Medical Genetics, ASST dei Sette Laghi, Varese, Italy (Siracusa); Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy (Genoni); Unit of Infectious and Tropical Diseases, ASST dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy (Grossi); Unit of Oral Medicine and Pathology, ASST dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy (Azzi, Tagliabue); Unit of Pathology, ASST dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy (Sessa); Unit of High Intensity Medicine, ASST dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy (Dentali); Cardiosurgery Intensive Care Unit, ASST dei Sette Laghi, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy (Severgnini); Transplants Intensive Care Unit, ASST dei Sette Laghi, Varese, Italy (Minoja); Intensive Care Unit, ASST dei Sette Laghi, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy (Cabrini); Unit of Ophthalmology, ASST dei Sette Laghi, Varese, Italy (Chiaravalli); Research Center in Epidemiology and Preventive Medicine (EPIMED), Department of Medicine and Surgery, University of Insubria, Varese, Italy (Veronesi); Unit of General, Emergency and Transplant Surgery, ASST dei Sette Laghi, Department of Medicine and Surgery, University of Insubria, Varese, Italy (Carcano); Chief Medical Officer, ASST dei Sette Laghi, Varese, Italy (Maffioli); Chancellor, University of Insubria, Varese, Italy (Tagliabue).

**Author Contributions:** Dr Azzolini had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Azzolini, Dentali, Cabrini, Carcano, Maffioli.

**Acquisition, analysis, or interpretation of data:** Azzolini, Donati, Premi, Baj, Siracusa, Genoni, Grossi, Azzi, Sessa, Dentali, Severgnini, Minoja, Cabrini, Chiaravalli, Veronesi, Tagliabue.

**Drafting of the manuscript:** Azzolini, Donati, Premi, Baj, Azzi, Dentali, Severgnini, Tagliabue.

**Critical revision of the manuscript for important intellectual content:** Azzolini, Donati, Premi,

Siracusa, Genoni, Grossi, Sessa, Minoja, Cabrini, Chiaravalli, Veronesi, Carcano, Maffioli.

**Statistical analysis:** Veronesi.

**Obtained funding:** Azzolini.

**Administrative, technical, or material support:**

Azzolini, Premi, Baj, Siracusa, Genoni, Grossi, Azzi, Dentali, Minoja, Tagliabue.

**Supervision:** Azzolini, Donati, Sessa, Severgnini, Cabrini, Chiaravalli, Carcano, Maffioli.

**Conflict of Interest Disclosures:** Dr Azzolini reported that his university received grants from Bayer and Novartis for ophthalmic projects and that Bayer, Novartis, Alcon, Allergan, Santen, Topcon, Thea, Dompé, and Bausch & Lomb provided grant funds to a nonprofit Italian ophthalmic association he chaired from 2016 to 2019. No other disclosures were reported.

**Funding/Support:** This study received financial support from the research resources of the Department of Medicine and Surgery, University of Insubria, Varese, Italy.

**Role of the Funder/Sponsor:** The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** We gratefully acknowledge the nursing staff of the various departments involved in the care of patients with COVID-19 and the laboratory personnel involved in this study. We thank Andrea Falco, BEng, for construction and management of the dedicated database for the electronic medical records (Eumeda platform hosted by Aruba Business srl). He was not compensated for his contributions.

## REFERENCES

- Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med*. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032
- She J, Jiang J, Ye L, Hu L, Bai C, Song Y. 2019 Novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies. *Clin Transl Med*. 2020;9(1):19. doi:10.1186/s40169-020-00271-z
- Sommer A. Humans, viruses, and the eye: early report from the COVID-19 front line. *JAMA Ophthalmol*. 2020;138(5):578-579. doi:10.1001/jamaophthalmol.2020.1294

- Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet*. 2020;395(10224):565-574. doi:10.1016/S0140-6736(20)30251-8

- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5

- Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017

- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7

- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-1069. doi:10.1001/jama.2020.1585

- Giwa AL, Desai A, Duca A. Novel 2019 coronavirus SARS-CoV-2 (COVID-19): an updated overview for emergency clinicians. *Emerg Med Pract*. 2020;22(5):1-28.

- Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25(3):23-30. doi:10.2807/1560-7917.ES.2020.25.3.2000045

- Habibzadeh P, Stoneman EK. The novel coronavirus: a bird's eye view. *Int J Occup Environ Med*. 2020;11(2):65-71. doi:10.15171/ijoom.2020.1921

- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3

- Sebastiani G, Massa M, Riboli E. Covid-19 epidemic in Italy: evolution, projections and impact of government measures. *Eur J Epidemiol*. 2020;35(4):341-345. doi:10.1007/s10654-020-00631-6

- Rizzi M, Castelli F, Latronico N, Focà E. SARS-CoV-2 invades the West: how to face a COVID-19 epidemic in Lombardy, Northern Italy? *Infect Med*. 2020;28(2):133-134.

- Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in case fatality rates (CFR) of COVID-19/SARS-CoV-2 in Italy and China. *J Infect Dev Ctries*. 2020;14(2):125-128. doi:10.3855/jidc.12600

- Asperges E, Novati S, Muzzi A, et al; COVID-19 IRCCS San Matteo Pavia Task Force. Rapid response to COVID-19 outbreak in Northern Italy: how to convert a

- classic infectious disease ward into a COVID-19 response centre. *J Hosp Infect*. 2020;S0195-6701(20)30119-5. doi:10.1016/j.jhin.2020.03.020
17. Gagliano A, Villani PG, Co' FM, et al. COVID-19 epidemic in the middle province of Northern Italy: impact, logistics, and strategy in the first line hospital. *Disaster Med Public Health Prep*. 2020;1-5.
18. Odone A, Delmonte D, Scognamiglio T, Signorelli C. COVID-19 deaths in Lombardy, Italy: data in context. *Lancet Public Health*. 2020;5(6):e310. doi:10.1016/S2468-2667(20)30099-2
19. Gomez LM, Meszaros VA, Turner WC, Ogbunugafor CB. The epidemiological signature of pathogen populations that vary in the relationship between free-living parasite survival and virulence. *Viruses*. 2020;12(9):E1055. doi:10.3390/v12091055
20. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. *J Infect*. 2020;81(1):e45-e50. doi:10.1016/j.jinf.2020.04.005
21. Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing viral shedding and infectivity of tears in coronavirus disease 2019 (COVID-19) patients. *Ophthalmology*. 2020;127(7):977-979. doi:10.1016/j.ophtha.2020.03.026
22. Zhou Y, Duan C, Zeng Y, et al. Ocular findings and proportion with conjunctival SARS-CoV-2 in COVID-19 patients. *Ophthalmology*. 2020;127(7):982-983. doi:10.1016/j.ophtha.2020.04.028
23. Willcox MD, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID-19. *Clin Exp Optom*. 2020;103(4):418-424. doi:10.1111/cxo.13088
24. Sun CB, Wang YY, Liu GH, Liu Z. Role of the eye in transmitting human coronavirus: what we know and what we do not know. *Front Public Health*. 2020;8:155. doi:10.3389/fpubh.2020.00155
25. Sun J, Zhu A, Li H, et al. Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient. *Emerg Microbes Infect*. 2020;9(11):991-993. doi:10.1080/22221751.2020.1760144
26. Jiang X, Luo M, Zou Z, Wang X, Chen C, Qiu J. Asymptomatic SARS-CoV-2 infected case with viral detection positive in stool but negative in nasopharyngeal samples lasts for 42 days. *J Med Virol*. 2020;92(10):1807-1809. doi:10.1002/jmv.25941
27. Song C, Wang Y, Li W, et al. Absence of 2019 novel coronavirus in semen and testes of COVID-19 patients. *Biol Reprod*. 2020;103(1):4-6. doi:10.1093/biolre/iaaa050
28. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053
29. National Center for Biotechnology Information. BLAST. Accessed October 31, 2020. <https://blast.ncbi.nlm.nih.gov/Blast.cgi>
30. Hajian-Tilaki K. Sample size estimation in epidemiologic studies. *Caspian J Intern Med*. 2011;2(4):289-298.
31. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. *J Med Virol*. 2020;92(6):589-594. doi:10.1002/jmv.25725
32. Liu Z, Sun CB. Conjunctiva is not a preferred gateway of entry for SARS-CoV-2 to infect respiratory tract. *J Med Virol*. 2020;92(9):1410-1412. doi:10.1002/jmv.25859
33. Guo D, Xia J, Shen Y, Tong J. SARS-CoV-2 may be related to conjunctivitis but not necessarily spread through the conjunctiva SARS-CoV-2 and conjunctiva. *J Med Virol*. 2020;92(10):1757-1758. doi:10.1002/jmv.25856
34. Peng Y, Zhou YH. Is novel coronavirus disease (COVID-19) transmitted through conjunctiva? *J Med Virol*. 2020. Published online March 16, 2020. doi:10.1002/jmv.25753
35. Zhang X, Chen X, Chen L, et al. The evidence of SARS-CoV-2 infection on ocular surface. *Ocul Surf*. 2020;18(3):360-362. doi:10.1016/j.jtos.2020.03.010
36. Azzi L, Carcano G, Dalla Gasperina D, Sessa F, Maurino V, Baj A. Two cases of COVID-19 with positive salivary and negative pharyngeal or respiratory swabs at hospital discharge: a rising concern. *Oral Dis*. 2020. Published online April 25, 2020. doi:10.1111/odi.13368
37. Peng L, Zhao X, Tao Y, Mi S, Huang J, Zhang Q. The effects of air pollution and meteorological factors on measles cases in Lanzhou, China. *Environ Sci Pollut Res Int*. 2020;27(12):13524-13533. doi:10.1007/s11356-020-07903-4
38. Setti L, Passarini F, De Gennaro G, et al. SARS-CoV-2 RNA found on particulate matter of Bergamo in Northern Italy: first evidence. *Environ Res*. 2020;188:109754. doi:10.1016/j.envres.2020.109754
39. Conticini E, Frediani B, Caro D. Can atmospheric pollution be considered a co-factor in extremely high level of SARS-CoV-2 lethality in Northern Italy? *Environ Pollut*. 2020;261:114465. doi:10.1016/j.envpol.2020.114465
40. Lombardia ARPA. Agenzia Regionale Protezione Ambiente: air data, March 2020. Accessed March 15, 2020. [https://www.arpalombardia.it/Pages/ARPA\\_Home\\_Page.aspx](https://www.arpalombardia.it/Pages/ARPA_Home_Page.aspx)
41. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 2020;395(10223):514-523. doi:10.1016/S0140-6736(20)30154-9
42. Phan LT, Nguyen TV, Luong QC, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. *N Engl J Med*. 2020;382(9):872-874. doi:10.1056/NEJMc2001272
43. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *N Engl J Med*. 2020;382(16):1564-1567. doi:10.1056/NEJMc2004973
44. Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. *J Hosp Infect*. 2016;92(3):235-250. doi:10.1016/j.jhin.2015.08.027
45. Han Y, Wu N, Zhu W, et al. Detection of HIV-1 viruses in tears of patients even under long-term HAART. *AIDS*. 2011;25(15):1925-1927. doi:10.1097/QAD.0b013e32834b3578
46. Qing H, Li Z, Yang Z, et al. The possibility of COVID-19 transmission from eye to nose. *Acta Ophthalmol*. 2020;98(3):e388. doi:10.1111/aos.14412
47. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular surface must not be ignored. *Lancet*. 2020;395(10224):e39. doi:10.1016/S0140-6736(20)30313-5
48. Kuo ICA. *Rashomon* moment? ocular involvement and COVID-19. *Ophthalmology*. 2020;127(7):984-985. doi:10.1016/j.ophtha.2020.04.027
49. Parrish RK II, Stewart MW, Duncan Powers SL. Ophthalmologists are more than eye doctors: in memoriam Li Wenliang. *Am J Ophthalmol*. 2020;213:A1-A2. doi:10.1016/j.ajo.2020.02.014
50. Peng X, Xu X, Li Y, Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental practice. *Int J Oral Sci*. 2020;12(1):9. doi:10.1038/s41368-020-0075-9
51. Lai THT, Tang EWH, Chau SKY, Li KKW. Reply to: Ocular manifestation, eye protection, and COVID-19. *Graefes Arch Clin Exp Ophthalmol*. 2020;258(6):1341. doi:10.1007/s00417-020-04663-2
52. Mungmungpantipantip R, Wiwanitkit V. Ocular manifestation, eye protection, and COVID-19. *Graefes Arch Clin Exp Ophthalmol*. 2020;258(6):1339. doi:10.1007/s00417-020-04662-3
53. Wan KH, Huang SS, Young AL, Lam DSC. Precautionary measures needed for ophthalmologists during pandemic of the coronavirus disease 2019 (COVID-19). *Acta Ophthalmol*. 2020;98(3):221-222. doi:10.1111/aos.14438
54. Zeri F, Naroo SA. Contact lens practice in the time of COVID-19. *Cont Lens Anterior Eye*. 2020;43(3):193-195. doi:10.1016/j.clae.2020.03.007
55. Lai THT, Tang EWH, Chau SKY, Fung KSC, Li KKW. Stepping up infection control measures in ophthalmology during the novel coronavirus outbreak: an experience from Hong Kong. *Graefes Arch Clin Exp Ophthalmol*. 2020;258(5):1049-1055. doi:10.1007/s00417-020-04641-8
56. Li JO, Lam DSC, Chen Y, Ting DSW. Novel coronavirus disease 2019 (COVID-19): the importance of recognising possible early ocular manifestation and using protective eyewear. *Br J Ophthalmol*. 2020;104(3):297-298. doi:10.1136/bjophthalmol-2020-315994
57. Siedlecki J, Brantl V, Schworm B, et al. COVID-19: ophthalmological aspects of the SARS-CoV 2 global pandemic. *Klin Monbl Augenheilkd*. 2020;237(5):675-680. doi:10.1055/a-1164-9381
58. Yan Y, Chen H, Chen L, et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019. *Dermatol Ther*. Published online March 13, 2020.
59. Ralli M, Candelori F, Cambria F, et al. Impact of COVID-19 pandemic on otology, ophthalmology and dental clinical activity and future perspectives. *Eur Rev Med Pharmacol Sci*. 2020;24(18):9705-9711. doi:10.26355/eurerv\_202009\_23062
60. Donati S, Caprani SM, Airaghi G, et al. Vitreous substitutes: the present and the future. *Biomed Res Int*. 2014;2014:351804. doi:10.1155/2014/351804
61. Wu P, Duan F, Luo C, et al. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. *JAMA Ophthalmol*. 2020;138(5):575-578. doi:10.1001/jamaophthalmol.2020.1291
62. Lange C, Wolf J, Auw-Haedrich C, et al. Expression of the COVID-19 receptor ACE2 in the human conjunctiva. *J Med Virol*. 2020. Published online May 6, 2020. doi:10.1002/jmv.25981
63. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052
64. Aiello F, Gallo Afflitto G, Mancino R, et al. Coronavirus disease 2019 (SARS-CoV-2) and colonization of ocular tissues and secretions: a systematic review. *Eye (Lond)*. 2020;34(7):1206-1211. doi:10.1038/s41433-020-0926-9
65. Xie C, Lu J, Wu D, et al. False negative rate of COVID-19 is eliminated by using nasal swab test. *Travel Med Infect Dis*. 2020;37:101668. doi:10.1016/j.tmaid.2020.101668